Advertisement

Molecular and Cellular Biochemistry

, Volume 462, Issue 1–2, pp 33–40 | Cite as

Overexpression LINC01082 suppresses the proliferation, migration and invasion of colon cancer

  • Wei Xiong
  • Jiyong Qin
  • Xinyi Cai
  • Wei Xiong
  • Qiuyan Liu
  • Cheng Li
  • Yunhe Ju
  • Qiaoli Wang
  • Yunfeng LiEmail author
  • Yi YangEmail author
Article
  • 90 Downloads

Abstract

Long non-coding RNAs (lncRNAs) are emerging as pivotal regulators in human cancer. LINC01082 was expressed as decreased in colon cancer by previous lncRNA-seq result and TCGA database, however, the role and function of LINC0182 is not clear in colon cancer. Here, we aimed to explore the role of LINC01082 in colon cancer for exploring the etiopathogenesis of colon cancer. RT-qPCR for LINC01082 expression in tissues (colon cancer vs. their matched adjacent non-cancerous tissues, ANT, n = 39) and cells (colon cancer cells vs. normal colon cells, n = 4) were performed. CCK-8 assay for proliferation of colon cancer, Transwell assay for migration and invasion were carried out in sw480 and sw620 cells. The results revealed that LINC01082 was significantly decreased in tissues and cell lines of colon cancer. Overexpressed LINC01082 significantly suppressed the proliferation ability of colon cancer cells. The migration and invasion of colon cancer cells were also suppressed after LINC01082 overexpression. These findings demonstrated that LINC01082 may act in suppressing the incidence and development of colon cancer via suppressing cell proliferation, migration and invasion, indicating that LINC01082 may act as a new tumor suppressor and may be a promising therapy target for colon cancer.

Keywords

LINC01082 Colon cancer Overexpression sw480 sw620 

Notes

Author contributions

WX, JQ, and XC conceived and designed the study. WX, JQ, XC, WX, QL, CL, YJ, and QW performed the experiments. WX wrote the paper. YL and YY reviewed and edited the manuscript. All authors read and approved the manuscript and agreed to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work is appropriately investigated and resolved.

Funding

This work was supported by the Training Program for Medical Reserve Talents of the Health and Family Planning Commission of Yunnan Province [Grant Number H-201641].

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

All experimental protocols were approved by the human Ethics Committee of Kunming Medical University. The written informed consent was obtained from all patients.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  2. 2.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMedGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67:177–193CrossRefGoogle Scholar
  4. 4.
    Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66:683–691CrossRefGoogle Scholar
  5. 5.
    Stein A, Atanackovic D, Bokemeyer C (2011) Current standards and new trends in the primary treatment of colorectal cancer. Eur J Cancer 47:S312–S314CrossRefGoogle Scholar
  6. 6.
    Azvolinsky A (2015) Colorectal cancer: to stack or sequence therapy? J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djv138 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Dai L, Cui X, Zhang X et al (2016) SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun 7:11996CrossRefGoogle Scholar
  8. 8.
    Zeng M, Zhu L, Li L, Kang C (2017) miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett 22:12CrossRefGoogle Scholar
  9. 9.
    Zhang Y, Lin C, Liao G et al (2015) MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget 6:32586–32601PubMedPubMedCentralGoogle Scholar
  10. 10.
    Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136:629–641CrossRefGoogle Scholar
  11. 11.
    Kopp F, Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell 172:393–407CrossRefGoogle Scholar
  12. 12.
    Li T, Xie J, Shen C et al (2016) Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35:1575–1584CrossRefGoogle Scholar
  13. 13.
    Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29:452–463CrossRefGoogle Scholar
  14. 14.
    Prensner JR, Chinnaiyan AM (2011) The emergence of lncRNAs in cancer biology. Cancer Discov 1:391–407CrossRefGoogle Scholar
  15. 15.
    Chen WM, Huang MD, Sun DP, Kong R, Xu TP, Xia R, Zhang EB, Shu YQ (2016) Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer. Oncotarget 7:9773–9787PubMedPubMedCentralGoogle Scholar
  16. 16.
    Szafranski P, Gambin T, Dharmadhikari AV et al (2016) Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins. Hum Genet 135:569–586CrossRefGoogle Scholar
  17. 17.
    Szafranski P, Dharmadhikari AV, Wambach JA et al (2014) Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins. Am J Med Genet A 164A:2013–2019CrossRefGoogle Scholar
  18. 18.
    Szafranski P, Karolak JA, Lanza D, Gajecka M, Heaney J, Stankewicz P (2017) CRISPR/Cas9-mediated deletion of lncRNA Gm26878 in the distant Foxf1 enhancer region. Mamm Genome 28:275–282CrossRefGoogle Scholar
  19. 19.
    Ousati Ashtiani Z, Pourmand G, Salami SA, Ayati M, Tavakkoly-Bazzaz J (2017) Dysregulated expression of long intergenic non-coding RNAs (LincRNAs) in urothelial bladder carcinoma. Int J Mol Cell Med 6:212–221PubMedPubMedCentralGoogle Scholar
  20. 20.
    Kazemzadeh M, Safaralizadeh R, Feizi MA, Somi MH, Shokoohi B (2017) Misregulation of the dependence receptor DCC and its upstream lincRNA, LOC100287225, in colorectal cancer. Tumori 103:40–43CrossRefGoogle Scholar
  21. 21.
    Wang G, Li Z, Zhao Q, Zhu Y, Zhao C, Li X, Ma Z, Zhang Y (2014) LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway. Oncol Rep 31:1839–1845CrossRefGoogle Scholar
  22. 22.
    Zhou M, Hu L, Zhang Z, Wu N, Sun J, Su J (2018) Recurrence-associated long non-coding RNA signature for determining the risk of recurrence in patients with colon cancer. Mol Ther Nucleic Acids 12:518–529CrossRefGoogle Scholar
  23. 23.
    Liu T, Zhang J, Chai Z, Wang G, Cui N, Zhou B (2017) Ginkgo biloba extract EGb 761–induced upregulation of LincRNA-p21 inhibits colorectal cancer metastasis by associating with EZH2. Oncotarget 8:91614–91627PubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang J, Lei ZJ, Guo Y et al (2015) miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells. Oncotarget 6:37852–37870PubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhou P, Sun L, Liu D, Liu C (2016) Long non-coding RNA lincRNA-ROR promotes the progression of colon cancer and holds prognostic value by associating with miR-145. Pathol Oncol Res 22:733–740CrossRefGoogle Scholar
  26. 26.
    Huang JZ, Chen M, Chen Gao XC, Zhu S, Huang H, Hu M, Zhu H, Yan GR (2017) A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell 68(171–184):e6Google Scholar
  27. 27.
    Sun N, Zhang G, Liu Y (2018) Long non-coding RNA XIST sponges miR-34a to promotes colon cancer progression via Wnt/beta-catenin signaling pathway. Gene 665:141–148CrossRefGoogle Scholar
  28. 28.
    Tian W, Du Y, Ma Y, Gu L, Zhou J, Deng D (2018) MALAT1-miR663a negative feedback loop in colon cancer cell functions through direct miRNA-lncRNA binding. Cell Death Dis 9:857CrossRefGoogle Scholar
  29. 29.
    Chen S, Bu D, Ma Y et al (2017) H19 overexpression induces resistance to 1,25(OH)2D3 by targeting VDR Through miR-675-5p in colon cancer cells. Neoplasia 19:226–236CrossRefGoogle Scholar
  30. 30.
    Zhou X, Yin C, Dang Y, Ye F, Zhang G (2015) Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 5:11516CrossRefGoogle Scholar
  31. 31.
    Tan Q, Zuo J, Qiu S, Yu Y, Zhou H, Li N, Wang H, Liang C, Yu M, Tu J (2017) Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker. Int J Oncol 50:1729–1738CrossRefGoogle Scholar
  32. 32.
    Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, Jia W (2013) Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol 30:588CrossRefGoogle Scholar
  33. 33.
    Shi D, Zheng H, Zhuo C, Peng J, Li D, Xu Y, Li X, Cai G, Cai S (2014) Low expression of novel lncRNA RP11-462C24. 1 suggests a biomarker of poor prognosis in colorectal cancer. Med Oncol 31:31CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyYunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China
  2. 2.Department of Colorectal SurgeryYunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical UniversityKunmingPeople’s Republic of China

Personalised recommendations